HABA Laboratories,Inc. (TYO:4925)
1,705.00
-1.00 (-0.06%)
Jun 19, 2026, 3:30 PM JST
HABA Laboratories,Inc. Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 5,784 | 4,743 | 3,959 | 4,817 | 5,651 |
Cash & Short-Term Investments | 5,784 | 4,743 | 3,959 | 4,817 | 5,651 |
Cash Growth | 21.95% | 19.80% | -17.81% | -14.76% | -0.21% |
Receivables | 1,253 | 1,196 | 1,259 | 975 | 1,126 |
Inventory | 2,570 | 2,921 | 3,713 | 3,368 | 3,151 |
Other Current Assets | 173 | 175 | 145 | 183 | 143 |
Total Current Assets | 9,780 | 9,035 | 9,076 | 9,343 | 10,071 |
Property, Plant & Equipment | 2,374 | 2,969 | 2,955 | 4,452 | 4,655 |
Long-Term Investments | 177 | 187 | 315 | 308 | 377 |
Other Intangible Assets | 112 | 93 | - | 315 | 346 |
Long-Term Deferred Tax Assets | 74 | 58 | 83 | 235 | 234 |
Other Long-Term Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 12,519 | 12,344 | 12,431 | 14,655 | 15,685 |
Accounts Payable | 323 | 236 | 303 | 475 | 336 |
Short-Term Debt | 100 | 500 | 600 | 200 | 300 |
Current Portion of Long-Term Debt | 480 | 589 | 754 | 801 | 785 |
Current Income Taxes Payable | 913 | 943 | 701 | 869 | 792 |
Other Current Liabilities | 530 | 390 | 455 | 453 | 318 |
Total Current Liabilities | 2,346 | 2,658 | 2,813 | 2,798 | 2,531 |
Long-Term Debt | 607 | 727 | 1,000 | 1,031 | 1,472 |
Long-Term Deferred Tax Liabilities | - | 2 | 50 | - | - |
Other Long-Term Liabilities | 30 | 30 | 62 | 54 | 46 |
Total Liabilities | 2,983 | 3,417 | 3,925 | 3,883 | 4,049 |
Common Stock | 696 | 696 | 696 | 696 | 696 |
Additional Paid-In Capital | 812 | 812 | 812 | 812 | 812 |
Retained Earnings | 9,163 | 8,554 | 8,128 | 10,398 | 11,257 |
Treasury Stock | -1,136 | -1,136 | -1,135 | -1,135 | -1,135 |
Comprehensive Income & Other | 1 | 1 | 5 | 1 | 6 |
Shareholders' Equity | 9,536 | 8,927 | 8,506 | 10,772 | 11,636 |
Total Liabilities & Equity | 12,519 | 12,344 | 12,431 | 14,655 | 15,685 |
Total Debt | 1,187 | 1,816 | 2,354 | 2,032 | 2,557 |
Net Cash (Debt) | 4,597 | 2,927 | 1,605 | 2,785 | 3,094 |
Net Cash Growth | 57.05% | 82.37% | -42.37% | -9.99% | 77.31% |
Net Cash Per Share | 1215.66 | 774.03 | 424.43 | 736.48 | 818.18 |
Filing Date Shares Outstanding | 3.78 | 3.78 | 3.78 | 3.78 | 3.78 |
Total Common Shares Outstanding | 3.78 | 3.78 | 3.78 | 3.78 | 3.78 |
Working Capital | 7,434 | 6,377 | 6,263 | 6,545 | 7,540 |
Book Value Per Share | 2521.76 | 2360.72 | 2249.36 | 2848.59 | 3077.07 |
Tangible Book Value | 9,424 | 8,834 | 8,506 | 10,457 | 11,290 |
Tangible Book Value Per Share | 2492.15 | 2336.12 | 2249.36 | 2765.29 | 2985.57 |